A recent study conducted in Basel has shown that TES triggers physiological processes in the retina of RP patients . After stimulation, an increased oxygen consumption in the retina was measured, which proves an increased cell activity. This supports the results of the studies carried out at the University Eye Hospital in Tübingen. In the pilot study EST I it was shown that TES can slow down the reduction in visual field loss . The follow-up study EST II showed significantly increased retinal cell activity . The safety of the application of the OkuStim system was clearly demonstrated in all clinical trials, including a multicentre observational study in 11 European clinics (TESOLA) [6, 7].
The highest decision-making body in the German health care system, the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), has attributed to TES therapy a potential for relevant benefit for patients with RP and issued a guideline for conducting a clinical trial .
The investigation is expected to start at the end of 2020.
Patient care and support
On the basis of the data obtained so far, the TES therapy is classified as safe by the Arbeitskreis Klinische Fragen (AKF) of PRO RETINA e.V., so that it can also be used outside the context of studies in RP patients. Furthermore, there are no objections to the use of the treatment in other generalised hereditary retinal dystrophies (cone and rod dystrophies, choroideremia, Usher syndrome, etc.) . The OkuStim system is only available on prescription.
Detailed informationen on the international availabiliy of the therapy you can finde here.